PROLEUKIN

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Canada, France, Netherlands, Singapore, Spain, UK.

Active ingredients

The drug PROLEUKIN contains one active pharmaceutical ingredient (API):

1	Aldesleukin UNII M89N0Q7EQR - ALDESLEUKIN
	Aldesleukin, a lymphokine, is produced by recombinant DNA technology and acts as a regulator of the immune response. The biological activities of aldesleukin and native human IL-2, a naturally occurring lymphokine, are comparable. The administration of aldesleukin in murine tumour models has been shown to reduce both tumour growth and spread. The exact mechanism by which aldesleukin-mediated immunostimulation leads to antitumour activity is not yet known.
	Read more about Aldesleukin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
PROLEUKIN Powder for solution for injection or infusion	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L03AC01	Aldesleukin	L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AC Interleukins
Discover more medicines within L03AC01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	534201301152416
CA	Health Products and Food Branch	02130181
ES	Centro de información online de medicamentos de la AEMPS	62287
FR	Base de données publique des médicaments	61637983, 68745374
GB	Medicines & Healthcare Products Regulatory Agency	47454, 47455
NL	Z-Index G-Standaard, PRK	33073
SG	Health Sciences Authority	10798P
US	FDA, National Drug Code	65483-116, 76310-022